文献速递乳房整形与再造

辅助化疗与保皮乳房切除即刻假体再造的手术并发症

Surgical Complications of Skin-Sparing Mastectomy and Immediate Implant-Based Breast Reconstruction in Women Concurrently Treated With Adjuvant Chemotherapy for Breast Cancer.
PubMed 文献 · Ann Plast Surg · 2021-01-01

本研究比较131例(139侧)接受辅助化疗的乳腺癌患者与491例(517侧)未接受辅助治疗患者在保皮乳房切除联合即刻假体乳房再造术后16周内的并发症。结果显示两组在轻微并发症、严重并发症、非计划手术、总干预次数及假体丢失比例上均无显著差异,化疗开始时间似乎也不影响并发症的发生或严重程度。

要点

  • 辅助化疗组与对照组轻微并发症和严重并发症发生率均无显著差异。
  • 两组非计划手术比例、总干预次数比例及假体丢失比例均无显著差异。
  • 化疗开始时间似乎不影响并发症的发生或严重程度。

核心结论

  • 需要辅助化疗的乳腺癌女性可潜在地从保皮乳房切除联合即刻假体乳房再造中获益。

研究设计与样本

  • 比较131例(139侧)接受辅助化疗女性与491例(517侧)未接受辅助治疗女性在联合术后16周内的并发症。

主要发现

  • 轻微并发症发生率在化疗组与对照组分别为13.7%和12.4%(P = 0.68),无显著差异。
  • 严重并发症发生率在化疗组与对照组分别为31.7%和29.4%(P = 0.60),无显著差异。
  • 需非计划手术的乳房比例在两组分别为0.29和0.24(P = 0.20),无显著差异。
  • 总干预次数比例在两组分别为0.34和0.33(P = 0.24),无显著差异。
  • 假体丢失比例在两组分别为0.72和0.67(P = 0.86),无显著差异。

临床怎么用

  • 对于需辅助化疗的乳腺癌患者,保皮乳房切除联合即刻假体乳房再造可考虑作为可选方案。

局限性

  • 化疗组与对照组在12项患者及手术相关特征中有7项存在显著差异,提示选择偏倚可能影响比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIM: To date, studies on adjuvant chemotherapy as a risk factor for the surgical outcome of combined mastectomy and breast reconstruction were hampered by the inclusion of mixed reconstructive cohorts of both delayed and immediate timing and of both autologous and implant-based techniques. Consequently, there is a paucity of data on the impact of adjuvant chemotherapy on surgical complication rates after combined skin-sparing mastectomy and immediate implant-based breast reconstruction. METHODOLOGY: We compared the postoperative complications that occurred within 16 weeks after this combined procedure in 131 women (139 breasts) treated with adjuvant chemotherapy with those in a control group of 491 women (517 breasts) not receiving any adjuvant therapy within 16 weeks. RESULTS: In line with the clinically indicated selection of women to undergo adjuvant chemotherapy, the interventional group differed significantly from the control group in 7 of the 12 patient- and procedure-related characteristics. The prevalence of minor complications (13.7% and 12.4%, respectively, P = 0.68) and major complications (31.7% and 29.4%, respectively, P = 0.60) did not differ significantly between the interventional group and the controls. The fraction of breasts that needed unscheduled surgery (0.29 and 0.24, respectively, P = 0.20), the fraction of total number of interventions (0.34 and 0.33, respectively, P = 0.24), and the fraction of implants lost (0.72 and 0.67, respectively, P = 0.86) did not differ significantly between both groups. The onset of chemotherapy, furthermore, seemed not to influence the occurrence or severity of complications. CONCLUSIONS: Like other women who have to undergo mastectomy, women who need to undergo adjuvant chemotherapy can potentially benefit from combined skin-sparing mastectomy and immediate implant-based breast reconstruction.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Kooijman MML, Hage JJ, Oldenburg HSA, et al. Surgical Complications of Skin-Sparing Mastectomy and Immediate Implant-Based Breast Reconstruction in Women Concurrently Treated With Adjuvant Chemotherapy for Breast Cancer. Ann Plast Surg. 2021. PMID: 32568758. doi:10.1097/SAP.0000000000002435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。